ASCO GU 2021 News : Episode 1

ASCO GU 2021 News: Dr. William Oh and Dr. Julie Graff

Feb 12, 2021

EP: 1.ASCO GU 2021 News: Dr. William Oh and Dr. Julie Graff

EP: 2.ASCO GU 2021 News: Drs. Bradley McGregor, David Braun, and

EP: 3.ASCO GU 2021 News: Dr. Petros Grivas and Dr. Arlene Siefker-Radtke

Related Videos

Lakshimi Nayak, MD

Bradley McGregor, MD

Christopher Lathan, MD, MS, MPH

Ursula A. Matulonis, MD

Ursula A. Matulonis, MD

Paul G. Richardson, MD

Paul L. Nguyen, MD, senior physician, director, Genitourinary Clinical Center for Radiation Oncology, Dana-Farber Cancer Institute, professor of radiation oncology, Harvard Medical School,

Guru P. Sonpavde, MD, medical director, Genitourinary (GU) Oncology, assistant director, Clinical Research Unit, Christopher K. Glanz Chair, Bladder Cancer Research, AdventHealth Cancer Institute

Michael S. Leapman, MD, MHS, associate professor of Urology, Clinical Program Leader, Prostate & Urologic Cancers Program, Yale Cancer Center

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance, associate professor, Division of Medical Oncology, University of Washington (UW) School of Medicine, clinical director, Genitourinary Cancers Program, UW Medicine, associate professor, Clinical Research Division, Fred Hutchinson Cancer Research Center

Related Content

Breast, Rectal, Kidney and Brain Cancer Phase 3 Trials Headline Dana-Farber Research at ASCO Annual Meeting

Gynecologic Cancer Experts Review 2023 SGO Research and Treatment Updates

April 10th 2023

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

March 20th 2023

Dana-Farber Researchers Report on the Safety and Activity of Immune Checkpoint Inhibitors in People Living with HIV and Cancer

Cabozantinib Plus Nivolumab and Ipilimumab Provides PFS Benefit in Advanced RCC

Breast, Rectal, Kidney and Brain Cancer Phase 3 Trials Headline Dana-Farber Research at ASCO Annual Meeting

Gynecologic Cancer Experts Review 2023 SGO Research and Treatment Updates

April 10th 2023

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

March 20th 2023

Dana-Farber Researchers Report on the Safety and Activity of Immune Checkpoint Inhibitors in People Living with HIV and Cancer

Cabozantinib Plus Nivolumab and Ipilimumab Provides PFS Benefit in Advanced RCC

Breast, Rectal, Kidney and Brain Cancer Phase 3 Trials Headline Dana-Farber Research at ASCO Annual Meeting

Gynecologic Cancer Experts Review 2023 SGO Research and Treatment Updates

April 10th 2023

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

March 20th 2023

Dana-Farber Researchers Report on the Safety and Activity of Immune Checkpoint Inhibitors in People Living with HIV and Cancer

Cabozantinib Plus Nivolumab and Ipilimumab Provides PFS Benefit in Advanced RCC

Related Content

Patrick Wen, MD

Breast, Rectal, Kidney and Brain Cancer Phase 3 Trials Headline Dana-Farber Research at ASCO Annual Meeting

Ursula A. Matulonis, MD; Robert L. Coleman, MD, FACOG, FACS; Cara Mathews, MD; Ramez N. Eskander, MD; Mansoor Raza Mirza, MD

Gynecologic Cancer Experts Review 2023 SGO Research and Treatment Updates

April 10th 2023

Dr Jennifer Ligibel

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

Sara M. Tolaney, MD, MPH

FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

March 20th 2023

Guru Sonpavde, MD

Dana-Farber Researchers Report on the Safety and Activity of Immune Checkpoint Inhibitors in People Living with HIV and Cancer

Toni K. Choueiri, MD

Cabozantinib Plus Nivolumab and Ipilimumab Provides PFS Benefit in Advanced RCC

Latest Conference Coverage

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

Sacituzumab Govitecan Elicits Consistent Safety in Patients With HR+/HER2– Breast Cancer, Regardless of UGT1A1 Status

Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.